Clinical Insights Gained by Refining the 2016 WHO Classification of Diffuse Gliomas With: EGFR Amplification, TERT Mutations, PTEN Deletion and MGMT Methylation

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-6177-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CAMKK2, Regulated by Promoter Methylation, Is a Prognostic Marker in Diffuse Gliomas

CNS Neuroscience and Therapeutics
PsychiatryMental HealthPhysiologyPharmacology
2016English

A Novel Analytical Model of MGMT Methylation Pyrosequencing Offers Improved Predictive Performance in Patients With Gliomas

Modern Pathology
Forensic MedicinePathology
2018English

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2016English

Prognostic or Predictive Value of MGMT Promoter Methylation in Gliomas Depends on IDH1 Mutation

Neurology
Neurology
2013English

TERT Promoter Mutations and Telomere Length in Adult Malignant Gliomas and Recurrences

Oncotarget
Oncology
2015English

Interplay Between TERT Promoter Mutations and Methylation Culminates in Chromatin Accessibility and TERT Expression

2019English

PTEN/MMAC1 Mutations in Primary Glioblastomas and Short-Term Cultures of Malignant Gliomas

Oncogene
Cancer ResearchGeneticsMolecular Biology
1998English

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

The Clinical Implications of Inconsistently Methylated Results From Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy